Suppliers and packagers for SPINRAZA

SPINRAZA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Biogen Idec	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531	NDA	Biogen Inc.	64406-058-01	1 VIAL, SINGLE-USE in 1 BOX (64406-058-01) / 5 mL in 1 VIAL, SINGLE-USE	2016-12-23

Spinraza Drug Manufacturing and Supply Chain

Last updated: February 19, 2026

Spinraza, the brand name for nusinersen, is a groundbreaking treatment for spinal muscular atrophy (SMA). Its production involves complex synthesis and strict quality control measures, relying on a specialized network of suppliers for its active pharmaceutical ingredient (API), key intermediates, and finished drug product.

What is the Active Pharmaceutical Ingredient (API) for Spinraza?

The API for Spinraza is nusinersen, a synthetic oligonucleotide. It is an antisense oligonucleotide that modulates the splicing of SMN2 pre-mRNA, increasing the production of full-length SMN protein [1]. The synthesis of this complex molecule requires specialized chemical manufacturing capabilities.

Who Manufactures Spinraza's API?

Biogen Inc. is the company that developed and markets Spinraza. While Biogen oversees the entire supply chain and manufacturing process, the large-scale production of nusinersen API is typically handled by contract manufacturing organizations (CMOs) with expertise in oligonucleotide synthesis. These CMOs are subject to rigorous auditing and quality agreements with Biogen. Specific CMOs involved in the production of nusinersen API are not publicly disclosed by Biogen due to proprietary reasons and competitive sensitivities. However, the pharmaceutical industry commonly utilizes specialized CMOs for such complex API manufacturing.

What are the Key Intermediates in Spinraza Production?

The synthesis of nusinersen involves a multi-step chemical process. Key intermediates are the building blocks formed during these steps before the final API is achieved. These typically include:

• Phosphoramidites: These are specialized nucleotide derivatives essential for oligonucleotide synthesis. The specific phosphoramidites used in nusinersen synthesis are proprietary but would include protected versions of cytosine, guanine, adenine, and thymine bases.
• Solid Supports: Oligonucleotide synthesis is often performed on a solid support (e.g., a resin bead) to facilitate purification and automation.
• Coupling Reagents: Chemicals like tetrazole or ETT (5-(Ethylthio)-1H-tetrazole) are used to activate phosphoramidites for coupling to the growing oligonucleotide chain.
• Oxidation/Sulfurization Reagents: Reagents such as iodine or sulfurizing agents are used to form the phosphodiester or phosphorothioate linkages, respectively, that connect the nucleotide units. Nusinersen contains phosphorothioate linkages, which provide increased nuclease resistance [2].

The precise identity and sourcing of these intermediates are critical to the overall API quality and are tightly controlled by Biogen and its manufacturing partners.

What are the Requirements for Suppliers of Spinraza Components?

Suppliers of all components for Spinraza, including raw materials, intermediates, and packaging materials, must meet stringent quality and regulatory standards. These requirements include:

• Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This ensures product quality, safety, and consistency.
• Quality Management Systems (QMS): Suppliers must have robust QMS in place, including change control, deviation management, CAPA (Corrective and Preventive Actions), and rigorous testing protocols.
• Auditing and Qualification: Biogen and its manufacturing partners conduct thorough audits of potential and existing suppliers to verify compliance with quality standards and contractual obligations. Supplier qualification is a continuous process.
• Regulatory Filings: Suppliers may be required to provide documentation for inclusion in Biogen's regulatory submissions to health authorities, demonstrating the suitability and quality of their materials or services.
• Supply Chain Security and Traceability: Robust systems for tracking materials from origin to finished product are essential to prevent counterfeiting and ensure the integrity of the supply chain.
• Environmental, Health, and Safety (EHS) Standards: Suppliers must demonstrate compliance with relevant EHS regulations.

Who Manufactures the Finished Drug Product of Spinraza?

The finished drug product, Spinraza (nusinersen) for injection, is manufactured and filled into its final dosage form under sterile conditions. This process, known as drug product manufacturing or fill-finish, is also typically outsourced to specialized CMOs or performed at Biogen's own manufacturing facilities. These facilities must comply with strict aseptic processing guidelines to ensure the sterility and safety of the injectable drug. Again, specific CMOs are usually not publicly disclosed by the pharmaceutical sponsor.

What are the Packaging Requirements for Spinraza?

Spinraza is supplied as a solution for intrathecal injection. The primary packaging components are critical for maintaining drug stability and sterility. These typically include:

• Vials: Sterilized glass vials, often Type I borosilicate glass, with a specific volume capacity to hold the formulated drug product.
• Stoppers: Sterile stoppers made of elastomeric materials (e.g., bromobutyl rubber) that are compatible with the drug formulation and provide a secure seal for the vial.
• Seals: Aluminum seals (caps) to secure the stopper onto the vial.
• Syringes and Needles (if pre-filled or for administration): While Spinraza is often supplied in vials for reconstitution or direct drawing into a syringe by healthcare professionals, some formulations or co-packaged components may include sterile syringes and needles.
• Secondary Packaging: Cartons, labels, and inserts providing product information, batch numbers, expiry dates, and patient instructions, all compliant with regulatory labeling requirements.

Suppliers of these primary packaging components must also meet GMP standards and undergo rigorous qualification processes to ensure material compatibility, leachables and extractables profiles, and dimensional integrity.

How is the Spinraza Supply Chain Managed?

Biogen manages the Spinraza supply chain through a combination of in-house oversight and strategic partnerships with qualified CMOs. Key aspects of supply chain management include:

• Demand Forecasting: Accurate forecasting of global demand is crucial to ensure sufficient supply and prevent stockouts, especially for a critical therapy like Spinraza.
• Inventory Management: Maintaining appropriate inventory levels of raw materials, intermediates, API, and finished product across the supply chain.
• Logistics and Distribution: Efficient and temperature-controlled transportation of materials and finished product to global markets. Spinraza requires specific storage conditions, typically refrigerated, to maintain its efficacy and stability [3].
• Risk Management: Identifying and mitigating potential risks to the supply chain, including geopolitical instability, natural disasters, quality issues at supplier sites, or raw material shortages. Business continuity plans are essential.
• Regulatory Compliance: Ensuring that all aspects of the supply chain, from raw material sourcing to final distribution, comply with the evolving regulatory landscape in all target markets.
• Quality Assurance and Control: Continuous monitoring and testing of materials and products at various stages of the supply chain to ensure they meet Biogen's specifications and regulatory requirements.

What are the Key Markets for Spinraza and Their Supply Implications?

Spinraza is approved and marketed in numerous countries worldwide, including the United States, European Union member states, Japan, and Canada. Each market has specific regulatory requirements for drug product registration, labeling, and distribution.

• United States: The FDA requires detailed information on API manufacturing, API and drug product specifications, stability data, and a robust supply chain integrity program.
• European Union: The EMA requires similar comprehensive data, with a focus on adherence to EU GMP guidelines and centralized marketing authorization procedures.
• Japan: The Pharmaceuticals and Medical Devices Agency (PMDA) has its own set of stringent requirements for API, drug product manufacturing, and quality control.

The global reach of Spinraza necessitates a supply chain capable of meeting diverse regulatory demands, ensuring timely and consistent delivery to patients in different regions. This often involves establishing regional distribution hubs and ensuring compliance with local importation and distribution laws.

What are the Challenges in Supplying Spinraza?

The supply of Spinraza faces several inherent challenges:

• Complexity of Oligonucleotide Synthesis: The multi-step chemical synthesis of nusinersen is technically demanding and requires specialized equipment and highly skilled personnel. This limits the number of potential manufacturers.
• High Cost of Raw Materials: Specialized reagents and building blocks for oligonucleotide synthesis are often expensive.
• Stringent Quality and Regulatory Hurdles: Maintaining GMP compliance and meeting evolving regulatory expectations for API and drug product manufacturing is a continuous challenge for both the sponsor and its suppliers.
• Temperature-Controlled Logistics: The need for refrigerated storage and transportation adds complexity and cost to the global distribution network.
• Demand Volatility: While Spinraza addresses a rare disease, accurate demand forecasting can be challenging due to patient diagnosis rates and access to treatment.
• Intellectual Property Protection: Ensuring the integrity of the patented manufacturing process and preventing counterfeiting is paramount.

Key Takeaways

• Spinraza's active pharmaceutical ingredient (API) is nusinersen, a synthetic oligonucleotide.
• Biogen Inc. oversees the production, with API and finished drug product manufacturing typically outsourced to specialized contract manufacturing organizations (CMOs) experienced in oligonucleotide synthesis and sterile fill-finish operations.
• Key intermediates include proprietary phosphoramidites and specialized reagents for oligonucleotide assembly.
• All suppliers must adhere to stringent Good Manufacturing Practices (GMP) and possess robust Quality Management Systems (QMS).
• The supply chain management for Spinraza involves complex logistics, risk mitigation, and global regulatory compliance, including temperature-controlled distribution.
• Challenges include the technical complexity of synthesis, high raw material costs, and strict regulatory requirements.

FAQs

1. Can any pharmaceutical company manufacture Spinraza's API?

No, the manufacturing of Spinraza's API, nusinersen, is a highly specialized process involving complex oligonucleotide synthesis. Only CMOs with demonstrated expertise, validated processes, and adherence to strict GMP guidelines can be considered. Furthermore, Biogen holds the intellectual property rights, and any manufacturing would occur under contract and strict quality agreements with Biogen.

2. How does Biogen ensure the quality of raw materials used in Spinraza?

Biogen implements a rigorous supplier qualification program. This includes thorough audits of supplier facilities, review of their Quality Management Systems, testing of incoming raw materials to verify they meet predefined specifications, and ongoing performance monitoring. Supply agreements detail quality expectations and require adherence to GMP.

3. What are the typical storage conditions for Spinraza?

Spinraza vials should be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light. It should not be frozen. These conditions are critical for maintaining the stability and efficacy of the drug [3].

4. Is the manufacturing process for Spinraza environmentally friendly?

The synthesis of complex molecules like oligonucleotides, while technically sophisticated, can have environmental considerations related to chemical usage, solvent waste, and energy consumption. Pharmaceutical companies and their CMOs are increasingly focused on implementing green chemistry principles and optimizing processes to minimize environmental impact, including solvent recovery and waste reduction initiatives, where feasible and compliant with regulatory standards. Specific data on Spinraza's environmental footprint is not publicly disclosed.

5. What happens if there is a disruption in the supply chain for Spinraza?

Biogen, like other pharmaceutical manufacturers, has business continuity plans in place to address potential supply chain disruptions. These plans can include qualifying secondary suppliers for critical raw materials or intermediates, maintaining safety stock of API and finished product, and working with logistics providers to reroute shipments. However, the complexity of oligonucleotide synthesis means that finding immediate alternative manufacturing capacity can be challenging.

Citations

[1] Spinraza Prescribing Information. (n.d.). U.S. Food & Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209663s014lbl.pdf

[2] Messer, A. (2013). Antisense Oligonucleotides. Chemical Reviews, 113(8), 5612–5634. https://doi.org/10.1021/cr400024f

[3] Biogen. (n.d.). Spinraza® (nusinersen) Full Prescribing Information. Retrieved from https://www.biogen.com/en_US/patients/spinraza/spinraza-prescribing-information.html